Human Papillomavirus (HPV) and Its Relationship to Cancer

What Is Human Papillomavirus (HPV)?

Human papillomavirus (HPV) is the most common sexually transmitted infection worldwide. Over 200 genotypes exist, of which approximately 40 infect the anogenital tract. HPV infections are extremely common — most sexually active adults will be infected at some point in their lives, usually without symptoms.

HPV and Cancer: The Link

While most HPV infections clear spontaneously within 1–2 years, persistent infection with high-risk HPV types (particularly HPV-16 and HPV-18) can cause cancer. High-risk HPV is responsible for: 100% of cervical cancers; 90% of anal cancers; 70% of oropharyngeal cancers; 65% of vaginal cancers; 50% of vulvar cancers; 35% of penile cancers.

Low-Risk vs High-Risk HPV

Low-risk HPV (types 6 and 11): cause genital warts (condyloma acuminata). Not associated with cancer. High-risk HPV (types 16, 18, 31, 33, 45 and others): cause cellular changes (dysplasia) that can progress to invasive cancer. The Bethesda system classifies cervical lesions from CIN1 to CIN3/carcinoma in situ based on HPV-associated dysplasia.

Prevention: HPV Vaccination

HPV vaccines (Gardasil 9, Cervarix) protect against the HPV types responsible for most HPV-related cancers. Primary schedule: 2 doses for children under 15, 3 doses for those 15 and older. Recommended age: 9–14 years before sexual debut, though effective up to age 45. Efficacy: Near 100% protection against vaccine-targeted HPV types when given before infection. Gender-neutral vaccination (boys and girls) is now recommended in most countries.

Screening

Cervical cancer screening with Pap smear and/or HPV testing every 3–5 years from age 25. Anal Pap smear for high-risk groups (MSM, HIV-positive individuals). Vaccination does not replace screening — vaccinated women should continue cervical cancer screening.